ANDREW KOZLOV

Andrew Kozlov stands as a pivotal figure in the advanced therapies investment landscape, serving as a Managing Partner and co-founder of 4BIO Capital. This leading international venture capital firm is exclusively dedicated to investing in the most innovative companies within the advanced therapies sector. Kozlov's leadership at 4BIO Capital is instrumental in shaping the future of medicine by backing transformative scientific breakthroughs.

At 4BIO Capital, Andrew Kozlov's investment focus is sharply honed on disruptive technologies that promise to revolutionize healthcare. This includes a broad spectrum of advanced therapies such as gene therapy, cell therapy, oligonucleotide therapy, RNA therapy, microbiome, and live biotherapeutics. He and his team seek out companies developing novel platforms and therapeutic candidates with the potential to address significant unmet medical needs across various disease areas. His strategic vision helps guide these early-stage companies through critical development phases, from preclinical research to clinical trials and market entry.

Kozlov's career background is distinguished by a unique blend of deep scientific understanding and extensive financial acumen. He holds a PhD in Molecular Biology, providing him with a profound grasp of the complex science underpinning advanced therapies. Complementing this scientific foundation, his MBA equips him with the strategic business insights necessary to evaluate market potential, manage risk, and foster commercial success. Prior to co-founding 4BIO Capital, Andrew accumulated significant experience in venture capital, private equity, and investment banking, consistently focusing on the life sciences sector. This diverse background has provided him with a comprehensive perspective on the entire investment lifecycle, from scientific diligence to deal structuring and portfolio management.

While specific individual investments are often attributed to the firm as a whole, Andrew Kozlov's influence is evident in 4BIO Capital's impressive portfolio of companies that are at the forefront of advanced therapy development. The firm has successfully identified and supported numerous ventures that have gone on to achieve significant milestones, including successful clinical trials, regulatory approvals, and strategic partnerships. These investments reflect Kozlov's commitment to backing ventures that not only offer substantial financial returns but also hold the promise of delivering life-changing treatments to patients worldwide. His work at 4BIO Capital continues to solidify the firm's reputation as a key driver of innovation and growth in the global advanced therapies market.